Search

Displaying results 5521 - 5530 of 10000 in total
  1. Drug

    Human papillomavirus type 18 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10302
    ApprovedInvestigational

    The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.

  2. Drug

    Sulbutiamine

    go.drugbank.com/drugs/DB13416
    Investigational

    The chronic administration of the drug has demonstrated to improve long term memory formation in mice. … It is highly lipophilic, allowing it to cross the blood-brain barrier more easily than other thiamine derivatives.

  3. Drug

    CE-224535

    go.drugbank.com/drugs/DB12113
    Investigational

    CE-224535 has been used in trials studying the treatment of Osteoarthritis.

    Categories: Purinergic P2X Receptor Agonists
  4. Drug

    Pentetreotide

    go.drugbank.com/drugs/DB12602
    ApprovedWithdrawn

    Pentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.

  5. Drug

    CE-326597

    go.drugbank.com/drugs/DB12694
    Investigational

    CE-326,597 has been used in trials studying the treatment of Obesity.

  6. Drug

    Gaxilose

    go.drugbank.com/drugs/DB12767
    ApprovedWithdrawn

    Gaxilose has been used in trials studying the diagnostic of Lactose Intolerance.

  7. Drug

    Parethoxycaine

    go.drugbank.com/drugs/DB19380
    ApprovedWithdrawn

    Parethoxycaine is a local anesthetic that was previously approved in the US.

  8. Drug

    Sirna-027

    go.drugbank.com/drugs/DB05896
    Investigational

    It is used to treat Macular degeneration. … VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails.

  9. Drug

    QXL138AM

    go.drugbank.com/drugs/DB18552
    Investigational

    QXL138AM is a masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a. It binds the CD138 protein on the surface of the tumour cells.

    Synonyms: Masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a
  10. Drug

    KC706

    go.drugbank.com/drugs/DB05157
    Investigational

    KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. … KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.